Syndex Bio announced the introduction of its proprietary mcPCR (methyl‑copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) conference in Orlando, Florida.
mcPCR enables ‘PCR for methylation’, the high-fidelity copying of both DNA methylation and the four-base genetic code during DNA amplification. This overcomes a fundamental limitation of PCR, which cannot amplify DNA methylation patterns that are critical for the detection of many diseases, including cancer. By enabling simpler, faster and more sensitive analysis of methylated DNA, mcPCR will help to transform the testing of clinical samples, especially in non-invasive and small-sample biopsies for early disease detection and recurrence monitoring.
Syndex Bio also announced the successful close of an oversubscribed $15.5 million seed financing led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind. The funds will support expansion of the mcPCR platform, development of clinical workflows and applications, and build‑out of the company’s R&D footprint in Cambridge, UK.
In conjunction with the financing, Gautam Kollu, former Chief Commercial Officer of Grail, joins the newly formed Board of Directors alongside Patrick Weiss (Chairman), Geoff Smith, Sean Kendall, and Eric Moessinger.
Visit Syndex Bio for more information
